-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Scientists from the University of North Texas Health Science Center recently discovered a new targeted treatment against melanoma by studying a rare genetic disorder called NGLY1 defect, the study was published in the international journal British Journal of Cancer.
Melanoma is a malignant skin cancer that kills about 9,000 people a year in the United States; in the paper, researchers delved into missing proteins that play a key role in the NGLY1 defect, which is so rare that there are only about 60 patients with the disease worldwide since the disease was diagnosed in 2012; and when researchers delved into the genetic disorder, they found that melanoma cells may be highly susceptible to NGLY1 deficiency.
researcher Dr Yu-Chieh Wang said people with NGLY1 defects were able to live normally but showed developmental delays, and when we looked at the developmental variation caused by NGLY1, we found that NGLY1 protein may be a very attractive cancer target. The researchers then delved into the protein's key role in the body and found that normal cells survive when NGLY1 function is inhibited, while melanoma cells die, and die quickly when melanoma cells lose NGLY1.
researchers say that by targeting NGLY1, it may be possible to eliminate melanoma cells without damaging healthy cells; the findings appear to be applied to other cancer studies, and the next step is to delve into why normal cells and certain individuals continue to survive when the NGLY1 protein is missing, while cancer cells do not. Once researchers identify potential targets, it may take more than 15 years for them to develop potential drug-targeted melanomas or other types of cancer. Researcher Wang said the findings of this paper may help reduce the burden of cancer in humans in the future, although we will continue to study to find a variety of anti-cancer strategies at a later stage.
s final researcher Victor Lin said: 'We have found a new type of anti-cancer target in this study, and we will continue to look further later to see if targeting the NDLY1 protein can help patients effectively fight multiple cancers.' (Bio Valley)